Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome
Agency: Department of Health and Human Services
Agency Tracking Number: DK080529
Phase: Phase I
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
INNOVATIVE BIOTHERAPIES, INC.
INNOVATIVE BIOTHERAPIES, INC., 401 W MORGAN RD, ANN ARBOR, MI, 48108
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Phone: () -
Phone: (734) 213-8350
AbstractDESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contr ibutors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under inv estigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic sho ck, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of mem brane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new t herapeutic approach to sepsis, SIRS and ARDS.
* information listed above is at the time of submission.